Back HIV Populations Children & Adolescents AIDS 2016: New Strategy Aims to End AIDS in Children by 2020

AIDS 2016: New Strategy Aims to End AIDS in Children by 2020


A new strategy to end pediatric AIDS, launched last month at the 21st International AIDS Conference (AIDS 2016) in Durban, calls for antiretroviral treatment services to reach 1.6 million children and 1.2 million adolescents by 2018. The "Super-Fast-Track" strategy is intended to close the gap between adult and pediatric treatment access, according to UNAIDS, and will pull together the actions of numerous agencies.

[Produced in collaboration with]

The strategy is intended to ensure that children and adolescents do not get left behind as treatment programs strive to achieve the UNAIDS 90-90-90 targets, and recognizes that scaling up diagnosis and treatment for children poses particular challenges that require different solutions from those employed for adults.

Ending Pediatric AIDS by 2020 May Be a Realistic Goal

Whereas AIDS diagnoses in children have declined dramatically in Uganda, Swaziland, and Burundi, and other countries including Thailand have already virtually eliminated mother-to-child transmission of HIV, achieving the goal of ending AIDS in children will require special efforts in several high-burden countries including Nigeria, South Africa, and India.

According to figures released by UNAIDS, Nigeria is falling far behind other countries in sub-Saharan Africa in providing antiretroviral treatment for children. Almost 260,000 children are estimated to be living with HIV infection in Nigeria, one-quarter of all those in the world; yet less than 1 in 5 are receiving antiretroviral therapy.

In contrast, in South Africa, where almost 240,000 children are living with HIV, around three-quarters are already receiving antiretroviral treatment. Zimbabwe and Kenya have achieved similarly high levels of treatment coverage among children as a result of strong efforts to improve infant HIV diagnosis and strong national commitments to improve treatment coverage for children.

HIV Treatment Cascade in Children: Diagnosis

As in adults, the HIV treatment cascade is a critical tool for monitoring the success of efforts to bring treatment to children and minimize the risk of pediatric AIDS. Diagnosis, the first step in the cascade, presents its own specific set of challenges for children. 

Virological testing for HIV DNA at 4-6 weeks of age is recommended for all HIV-exposed infants. Point-of-care testing is most likely to ensure that the infant is not lost to follow-up and that treatment can be started promptly. Infants with HIV are at especially high risk of death during the first months of life, but up to half of infants tested for HIV in 4 countries never received those results, and as a consequence could not receive antiretroviral treatment.

Improving access to infant diagnostic tests is essential for achieving the first "90" for children. Coverage of early infant diagnostic tests has improved dramatically in several countries since 2012, but even in some of the best-improving countries such as Zimbabwe and Mozambique, only half of HIV-exposed infants were tested in 2015, UNAIDS estimates.

Cost remains a major barrier, Badara Samb, Director of UNAIDS Office of Special Initiatives told

"We needed to reduce the cost and to make it friendlier. That’s why we have been working with a number of manufacturers to see if we can develop point-of-care diagnosis," she said. "Today, we have technology that is available through 2 companies that makes early infant diagnosis at the point of care possible. We have been able to reduce the price with a partnership with Roche, and we are trying to push for competition to lower the price."

Roche cut the price of its early infant diagnostic test to US$9.40 per test in 2015 after negotiations with the Diagnostics Access Initiative, formed to reduce the cost of HIV viral load testing.

A major new push to improve early infant diagnosis will begin later this year to make point-of-care testing more widely available, using World Health Organization (WHO) prequalified products (Alere HIV-1/2 Detect and Gene Xpert). As part of this initiative, the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is working with partners to speed up early infant diagnosis using new diagnostic kits recently prequalified by WHO in 9 countries in sub-Saharan Africa. The project aims to test 320,000 children by 2019 and to provide test results within 48 hours.

If diagnosis is missed in infants, or if HIV-exposed infants are not tested at the end of the breastfeeding period, children can go for years without HIV diagnosis due to lack of healthcare provider-initiated testing.

"We’ve focused on early infant diagnosis, but the yield we have achieved through that is very low and data coming from countries says we should be looking elsewhere. Provider-initiated testing has got to be part of this," Chewe Luo of UNICEF told a meeting organized by WHO at AIDS 2016.

Provider-initiated testing needs to include opportunities to test outside medical facilities. Lesotho’s health minister Molotsi Monyamane told the pediatric strategy launch meting that national policy has been changed to allow lay counselors to test children at community-based facilities, and mobile outreach services are providing under-5 and maternal-child health services that include HIV testing.

Making HIV tests a routine part of child health care would go a long way toward improving diagnosis for children, and community-based campaigns such as Lesotho’s "Know Your Child’s Status" are needed to ensure that children can be diagnosed before HIV disease progression.

Tuberculosis (TB) clinics are an important site for diagnosing adolescents. Francesca Celletti of EGPAF reported results on the yield of positive diagnoses at different types of EGPAF-supported sites in Kenya, showing that TB clinics are vastly more likely to identify adolescents with HIV than other testing sites, underlining the importance of adolescent-friendly TB services.

Prompt Initiation of Treatment

In 2015 WHO recommended immediate treatment initiation for all children under the age of 5 diagnosed with HIV regardless of CD4 cell count. Ren Minghui of WHO told the pediatric strategy meeting that almost all high-burden "Fast-Track" countries have already switched to treating all children regardless of age, or will do so later in 2016.

Although treatment coverage worldwide is higher among children than among adults, UNAIDS estimates that the number of children on treatment will need to increase by at least 83% (approximately 730,000 enrolled on treatment) by 2020 to achieve an end to pediatric AIDS. As well as delays in diagnosis, there are also challenges in linking children to antiretroviral therapy, not least a lack of facilities able to provide treatment for children.

Simplifying therapy for children is essential both for delivery of treatment at the facility level and for achievement of the third "90," viral suppression. Despite considerable work to make pediatric drug formulations easier to dose, the range of antiretroviral products available for children is still limited and only 1 fixed-dose combination. Pellets that can be sprinkled onto food are an important means of helping younger children to take medication, but so far only 1 product -- lopinavir/ritonavir (Kaletra or Aluvia) -- is available in this form. The Drugs for Neglected Diseases Initiative is working with the Indian manufacturer Cipla to develop a pair of 2-drug combinations for children in the form of oral pellets, and hopes that products will be available by 2018. The products will combine lopinavir/ritonavir and lamivudine with either abacavir or zidovudine.

Viral Suppression

Viral suppression remains more challenging in children than in adults, due in part to adherence difficulties, but also due to the continued use of suboptimal drug combinations containing nevirapine (Viramune). Children with HIV who acquire nevirapine resistance as a result of maternal treatment failure, either at delivery or during breastfeeding, will continue to have reduced sensitivity to nevirapine, and limited use of the recommended alternative regimen containing lopinavir/ritonavir often leads to treatment failure in these children.

Just as for adults, innovations in service delivery can improve retention in care, whether it is through family-centered appointment systems, nurse-led clinics, or incorporation of peer support into clinical services. Decentralization of services to bring them closer to families has been shown to improve retention in care in a study of 5 African countries, cutting loss to follow-up by between half and three-quarters.

Conclusion: The Moral Imperative

The new emphasis on pediatric treatment is intended to mobilize resources and galvanize action, Samb told

"We are not putting the right resources into pediatric treatment," he said. "We have the means to end it once and for all, so why are we not prioritizing HIV treatment for children? Here we have an ethical and a moral imperative, and we also need to be more longsighted and see that even though these children are a small number [relative to the adult epidemic] they are still the next generation."



Start Free, Stay Free, AIDS Free: Finishing the Job of the Global Plan. 21st International AIDS Conference. Durban, July 18-22, 2016. Session MOSA13.

A Global Partnership to End Paediatric AIDS by 2020. 21st International AIDS Conference. Durban, July 18-22, 2016. Session TUSA06.

C Luo, P Idele, T Porth, et al. Where are we with elimination of new HIV infections among children? 21st International AIDS Conference. Durban, July 18-22, 2016. Abstract WEPEE561.